These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27992871)

  • 1. ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ.
    Breyer J; Otto W; Wirtz RM; Wullich B; Keck B; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Laible M; Schlombs K; Eidt S; Denzinger S; Burger M; Hartmann A;
    Urol Int; 2017; 98(3):282-289. PubMed ID: 27992871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).
    Breyer J; Wirtz RM; Laible M; Schlombs K; Erben P; Kriegmair MC; Stoehr R; Eidt S; Denzinger S; Burger M; Hartmann A; Otto W
    Virchows Arch; 2016 Nov; 469(5):547-552. PubMed ID: 27514658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.
    Breyer J; Wirtz RM; Erben P; Rinaldetti S; Worst TS; Stoehr R; Eckstein M; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W
    BJU Int; 2019 Jan; 123(1):187-196. PubMed ID: 30120861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies.
    Breyer J; Wirtz RM; Otto W; Laible M; Schlombs K; Erben P; Kriegmair MC; Stoehr R; Eidt S; Denzinger S; Burger M; Hartmann A
    Oncotarget; 2017 Sep; 8(40):67684-67695. PubMed ID: 28978063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
    Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
    Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients.
    Breyer J; Wirtz RM; Otto W; Erben P; Worst TS; Stoehr R; Eckstein M; Denzinger S; Burger M; Hartmann A
    Cancer Immunol Immunother; 2018 Mar; 67(3):403-412. PubMed ID: 29150702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
    Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
    BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
    Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
    Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
    ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC).
    Spachmann PJ; Azzolina V; Weber F; Evert M; Eckstein M; Denzinger S; Burger M; Otto W; Breyer J
    Pathol Oncol Res; 2020 Jul; 26(3):1625-1632. PubMed ID: 31506803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
    Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
    Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Factors Predictive of Recurrence and Progression for Patients Who Suffered Initial Recurrence After Transurethral Resection of Stage pT1 Bladder Tumor in Chinese Population: A Retrospective Study.
    Shen Z; Xie L; Chen T; Tian D; Liu X; Xu H; Zhang Y; Wu Z; Sha N; Xing C; Ding N; Hu H; Wu C
    Medicine (Baltimore); 2016 Feb; 95(5):e2625. PubMed ID: 26844474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in patients with stage pT0/pT1/pTa in the radical cystectomy specimen.
    Husillos-Alonso A; Herranz Amo F; Subirá-Ríos D; Díez-Cordero JM; Moralejo-Gárate M; López-López E; Piñero-Sánchez J; Ogaya Pinies G; Lledó-García E; Hernández-Fernández C
    Arch Esp Urol; 2013 Oct; 66(8):787-95. PubMed ID: 24136482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.